ICU Medical (ICUI) FY2016 results: revenue $379 million, up 11.0% on the year
ICU Medical Inc. (ICUI) reported revenue of $379 million for fiscal 2016, the year ended 31 December 2016, up 11.0% on the year before. Net income was $63 million, up 40.2%, and diluted earnings per share $3.66. The figures are the company's own, from the 10-K it filed with the SEC on 1 March 2017.
Revenue
$379 million
+11.0% on the year
FY2009FY2016
Operating margin
21.9%
20.1% a year earlier
FY2009FY2016
Net income
$63 million
+40.2% on the year
FY2009FY2016
Diluted EPS
$3.66
+34.1% on the year
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
379
342
309
+11.0%
Cost of revenue
178
161
158
+10.6%
Gross profit
201
181
151
+11.4%
Gross margin
53.1%
52.9%
49.0%
Research and development
13.0
15.7
18.3
-17.6%
Selling, general and administrative
89.4
83.2
88.9
+7.5%
Operating income
82.9
68.6
39.0
+21.0%
Operating margin
21.9%
20.1%
12.6%
Interest expense
0.1
0.0
n/a
+202.6%
Pre-tax income
85.2
69.7
39.8
+22.2%
Income tax
22.1
24.7
13.5
-10.7%
Effective tax rate
25.9%
35.5%
33.8%
Net income
63.1
45.0
26.3
+40.2%
Net margin
16.6%
13.2%
8.5%
Diluted EPS
$3.66
$2.73
$1.68
+34.1%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
89.9
64.2
66.3
+40.1%
Capital expenditure
23.4
13.0
16.6
+79.9%
Free cash flow
66.6
51.2
49.7
+30.0%
Free cash flow margin
17.6%
15.0%
16.1%
Cash from investing
16.3
-11.2
-21.8
Cash from financing
2.5
15.7
13.6
-84.2%
Depreciation and amortisation
19.1
18.1
19.4
+5.4%
Share-based compensation
15.2
12.8
9.6
+18.8%
Buybacks
17.2
1.5
5.8
+1,031.6%
Diluted shares, weighted
17m
16m
16m
+4.6%
Shares outstanding at period end
16m
16m
16m
+1.6%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
660
580
508
+13.8%
Debt
0.0
0.0
0.0
Other liabilities
44.5
47.0
32.9
-5.2%
Total liabilities and equity
705
627
541
+12.4%
Fixed assets
85.7
74.3
86.1
+15.3%
Goodwill
5.6
6.5
1.5
-13.7%
Intangible assets
22.4
23.9
7.1
-6.5%
Investments
0.0
41.2
71.0
Cash and equivalents
445
336
276
+32.4%
Receivables
56.2
57.8
39.1
-2.9%
Inventory
49.3
43.6
36.9
+12.9%
Other assets
40.5
43.2
23.7
-6.3%
Total assets
705
627
541
+12.4%
10-K for the year ended 31 December 2016, filed 1 March 2017: the filing.